Zomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample Dilution
The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab
ANN ARBOR, MI / / May 21, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced an update to one of their fastest growing assays, insulin for equine plasma. This update increases the test's already industry-leading point of care dynamic range and adds a new function, automatic sample dilution, that allows a veterinarian to measure insulin at the highest levels with no additional steps or increase in time-to-result on the TRUFORMA In-Clinic Biosensor Testing Platform.
"When we introduced our equine insulin assay in October of 2024, one of the most frequent requests we received was for a dilution protocol to measure insulin level in horses suspected to be greater than 250 µU/mL," said Ian Harmon, Senior Director, R&D. Ian continues, "In response, rather than validating an external dilution protocol that would involve additional steps for the veterinarian and staff, our engineers designed a way to have the TRUFORMA device automatically dilute the sample for them and run the test with no additional time or steps. The user simply selects the 'Auto Dilute' option from the test menu screen, and the TRUFORMA device takes it from there. The uniqueness of our single-use test cartridges allows us this flexibility of design and is something that no other platform can do."
By having the TRUFORMA device perform the dilution automatically on the existing test cartridge, consistency from test-to-test is assured and the staff is freed from having to perform a tedious additional task.
The Zomedica R&D team was also able to increase the already industry-leading dynamic range of the standard (or default, undiluted) in-clinic insulin test by 60%! The chart below illustrates the new dynamic ranges for both the default and auto dilute protocols, making the TRUFORMA insulin test for equine plasma the most dynamic test of its kind in the world.
T.J. Barclay, DVM, Senior Professional Services Veterinarian for Zomedica, commented, "In recent years, insulin dysregulation in horses and ponies has been increasingly recognized as the most significant risk factor for developing laminitis. In the more severe cases, insulin levels may be above a test's upper limit of detection, rendering us unable to determine by serial monitoring if our treatment is effective. In those cases, quantifying extremely high insulin levels has required sending samples to a reference lab where they can perform sample dilutions. Having a device that gives us results in minutes at the point of care that has a both a high dynamic range by default and a process that dilutes the sample on demand covers all patient types we may encounter, helping us make quicker decisions during the treatment and monitoring process."
With the increased dynamic range and new automatic dilution function, along with the consistency, accuracy, and convenience of the original assay, Zomedica has set a new standard for point of care equine insulin testing.
The TRUFORMA Insulin assay for equine plasma with automatic sample dilution may be ordered now from Zomedica. For more information, visit www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relationsinvestors@zomedica.com1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Opinion - It's hurricane season again, and public health hangs in the balance
June marks the beginning of the 2025 Atlantic hurricane season, and forecasters are warning of above-average activity. More than half of U.S. coastal areas should plan to face a major hurricane of Category 3, 4, or 5. If our 2024 experience is a reliable predictor, we can anticipate more than $100 billion in damage, more than 100 fatalities and an increasingly problematic, if overlooked, element of these disasters: the threat to public health. Hurricanes and other water-centric events, like flooding, are creating ideal environments for the transmission of infectious diseases, from mold exposure to flesh-eating diseases to mosquito-borne viruses. Clusters of a potentially fatal infection caused by Vibrio bacteria, which can cause severe diarrhea and necrotizing skin lesions, hit Florida after Hurricane Ian in 2023. Cases in 2024 exceeded that total, with high burdens in Florida counties that experienced the worst flooding from Hurricane Helene. In Texas last summer, health officials warned the public of the risk of contracting West Nile virus post-Hurricane Beryl. Mosquito-borne illness is possible wherever there are mosquitoes. Florida, California and Texas all experienced locally acquired cases of dengue fever in 2024. Chikungunya, which can result in lifelong physical debilitation, is also present in the United States, with travel-associated and locally acquired cases being documented in Gulf states as recently as 2019. Several deaths from Eastern equine encephalitis occurred last year in northeastern states, with several towns instituting curfews to curb the mosquito-borne threat. Rises in mosquito populations are a well-documented hazard after hydrologic disasters like hurricanes, tsunamis and floods. These events can compromise sewage pipes, contaminate drinking water and result in diffuse areas of standing water that become breeding grounds for mosquitoes. Emergency preparedness professionals have long understood the risk. What's changing is the frequency of billion-dollar disasters — and with them, we suspect, greater damage, flooding, and disease risk. The good news is that we can leverage past experience, predictive models and tools like state and regional medical stockpiles to mitigate some of the worst health impacts. By strategically positioning medical supplies and countermeasures closer to the point of need, health authorities can significantly reduce response time, minimize logistical challenges and save lives. A number of states already have medical stockpiles for basic medications and personal protective equipment; others are creating or updating legislative authorities for them. These stockpiles generally lack federal support and medical countermeasures for high-consequence threats. The utility of state or regional caches could be expanded to include emerging needs like vaccines, treatments and diagnostics for vector-borne infections. Congress authorized the Department of Health and Human Services to conduct a pilot program matched by local funds for state stockpiling of medical countermeasures and other supplies for public health emergencies. The Biden administration did not request funding for state stockpiles and Congress has not appropriated funds for the program, however, stagnating the initiative. Funding is the number one type of support that jurisdictions say they need to help them establish and maintain stockpiles. Investing in state or regional stockpiles is a cost-effective approach to emergency preparedness. It minimizes the need for last-minute, high-cost procurements during crises, places more autonomy in the hands of states and helps maintain health care system resilience. President Trump's executive order on preparedness recognizes ownership of preparedness at the state and local level, and calls on federal policy to help empower state and local jurisdictions to make smart infrastructure choices. This same ethos can extend to public health preparedness. Last year's final report of the congressional Select Subcommittee on the Coronavirus Pandemic concluded that state stockpiles can provide a tailored local complement to the federal Strategic National Stockpile. As natural disasters increase in frequency and intensity, the federal government can support local decision-makers in meeting their communities' unique public health readiness needs. During COVID-19, many local officials did not know what was in the federal stockpile. Drawing stockpiles closer to the communities that will need them, tied to input from local, state or regional medical advisory groups, would increase awareness of stockpile contents and enable tailored input to support assets these communities need. Redundancies built into state or regional caches could allow local health care providers access to critical supplies that allow them to meet medical standards of practice even in a crisis. State stockpiles could facilitate greater efficacy of vendor-managed inventories and improve the quality and efficiency of supply rotations. Especially for countermeasures that have cold chain requirements or other complicated logistics, the federal role can be to provide the training and best practices to allow jurisdictions to successfully store and distribute these assets when needed. COVID-19 revealed a national unpreparedness to increase production rationally based on identifiable gaps pre-disaster. For example, better local input on necessary ventilator functionalities would have improved the production of quality devices as demand surged, rather than devices produced by auto manufacturers that were failures. State and regional stockpiles can reverse this underpreparedness and empower local communities. Congress should show its federal support by extending the authorized timeline for the state stockpile program and, critically, funding it commensurately in the coming appropriations cycle. By strategically positioning medical supplies and countermeasures closer to the point of need, a federal-regional-state partnership can significantly reduce response time, minimize logistical challenges and save lives before future hurricane seasons and other regional disasters occur. Craig Vanderwagen is a former assistant secretary for preparedness and response in the Department of Health and Human Services and the founder and general manager of East West Protection, LLC, which provided private and public sector disaster preparedness support. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
District Files NI 43-101 Technical Report for the Viken Deposit Mineral Resource Estimate in Sweden
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - District Metals Corp. (TSXV: DMX) (Nasdaq First North: DMXSE SDB) (OTCQB: DMXCF) (FSE: DFPP); ("District" or the "Company") reports that it has filed the independent NI 43-101 Technical Report for its 100%-owned Viken Energy Metals Property in Jämtland County, Sweden, related to the updated Mineral Resource Estimate ("MRE") for the Property announced on April 29, 2025. The Technical Report titled "Updated Mineral Resource Estimate and Technical Report on the Viken Energy Metals Project, Jämtland County, Sweden" (the "Technical Report") was prepared by P&E Mining Consultants Inc. ("P&E") in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and has an effective date of April 25, 2025. The Technical Report details the MRE comprising: Table 1: 2025 Pit-Constrained Mineral Resource Estimate for the Viken Deposit(1-7) Indicated TonnesM U3O8ppm V2O5ppm Moppm Nippm Cuppm Znppm P2O5ppm Ce2O3ppm Y2O3ppm La2O3ppm K2O% 456 175 2,836 257 330 113 411 2,461 88 492 7 3.84Mlb Mt ContainedMetal 176 2,851 258 332 114 413 1.12 0.04 0.22 0.00 17.53Inferred TonnesM U3O8ppm V2O5ppm Moppm Nippm Cuppm Znppm P2O5ppm Ce2O3ppm Y2O3ppm La2O3ppm K2O% 4,333 161 2,543 240 321 118 417 2,541 88 528 7 3.70Mlb Mt ContainedMetal 1,538 24,295 2,293 3,067 1,127 3,984 11.01 0.38 2.29 0.03 160.27 Notes: (1) Mineral Resources which are not Mineral Reserves do not have demonstrated economic viability. The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. (2) The Inferred Mineral Resource in this MRE has a lower level of confidence than that applied to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that the majority of the Inferred Mineral Resource could be upgraded to an Indicated Mineral Resource with continued exploration. (3) The Mineral Resource in this MRE was estimated using the Canadian Institute of Mining, Metallurgy and Petroleum (CIM), CIM Standards on Mineral Resources and Reserves, Definitions (2014) and Best Practices Guidelines (2019) prepared by the CIM Standing Committee on Reserve Definitions and adopted by the CIM Council. (4) The MRE was based on consensus economics forecast US$ metal prices of $72/lb U3O8, $5/lb V2O5, $17/lb Mo, $8.50/lb Ni, $4.25/lb Cu and $1.30/lb Zn with respective process recoveries of 80%, 80%, 70%, 70%, 50% and 75%, (5) Overburden, waste and mineralized US$ mining costs per tonne mined were respectively $2.00, $2.50 and $3.00. (6) Processing and G&A US$ costs per tonne processed were respectively $20 and $2. (7) Constraining pit shell slopes were 45 degrees. The Authors of the Technical Report have recognized that the Viken Energy Metals Property contains Targets for further exploration with a potential range of 980 Mt to 1,040 Mt at grade ranges of 140 to 180 ppm U3O8, 2,170 to 2,740 ppm V2O5 and 210 to 260 ppm Mo. These Targets for further exploration are based on the estimated strike length, depth and width of the mineralization, as supported by intermittently-spaced drill holes and observations of mineralized outcrops. The Targets for further exploration are located adjacent to the margins of the current MRE. The potential quantities and grades of the targets for further exploration are conceptual in nature. There has been insufficient work done by a Qualified Person to define these estimates as Mineral Resources. The Company is not treating these estimates as Mineral Resources, and readers should not place undue reliance on these estimates. Even with additional work, there is no certainty that these estimates will be classified as Mineral Resources. In addition, there is no certainty that these estimates will prove to be economically recoverable. The Technical Report is available on SEDAR+ ( under District's issuer profile. Technical Information All scientific and technical information in this news release has been prepared by, or approved by Garrett Ainsworth, President and CEO of the Company and Eugene Puritch, FEC, CET, President of P&E Mining Consultants Inc. Messrs. Ainsworth and Puritch are each a Qualified Person for the purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101"). Mr. Puritch is independent of the Company. Mr. Puritch is responsible for reporting Mineral Resources for the Viken Energy Metals Property. Additional P&E independent Qualified Persons contributing to the MRE are William Stone, PhD, Fred Brown, David Burga, Jarita Barry, and D. Grant Feasby, About District Metals Corp. District Metals Corp. is led by industry professionals with a track record of success in the mining industry. The Company's mandate is to seek out, explore, and develop prospective mineral properties through a disciplined science-based approach to create shareholder value and benefit other stakeholders. District is a polymetallic exploration and development company focused on the Viken and Tomtebo Properties in Sweden. The Viken Property covers 100% of the Viken Energy Metals Deposit, which contains the largest undeveloped Mineral Resource Estimate of uranium in the world along with significant Mineral Resource Estimates of vanadium, molybdenum, nickel, copper, zinc, and other important and critical raw materials. The advanced exploration stage Tomtebo Property is located in the Bergslagen Mining District of south-central Sweden and is situated between the historical Falun Mine and Boliden's Garpenberg Mine that are located 25 km to the northwest and southeast, respectively. Two historic polymetallic mines and numerous polymetallic showings are located on the Tomtebo Property along an approximate 17 km trend that exhibits similar geology, structure, alteration and VMS/SedEx style mineralization as other significant mines within the district. For further information on the Tomtebo Property, please see the technical report titled "NI 43-101 Update Technical Report on the Tomtebo Project, Bergslagen Region of Sweden" dated effective October 15, 2020 and amended and restated on February 26, 2021, which is available on SEDAR+ at On Behalf of the Board of Directors "Garrett Ainsworth" President and Chief Executive Officer(604) 288-4430 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding "Forward-Looking Information" This news release contains certain statements that may be considered "forward-looking information" with respect to the Company within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved" and any similar expressions. In addition, any statements that refer to expectations, predictions, indications, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information in this news release relating to the Company include, among other things, statements relating to the Viken Deposit; results of the Viken Deposit MRE and size thereof; realization of MRE; future price of metals; potential increases to the Viken Deposit MRE; future economic studies and timing thereof; potential lifting of the current ban on uranium mining in Sweden; the results of exploration and drilling and interpretations thereof, and future exploration; the benefits of mining Sweden; the Company's Swedish polymetallic properties; the Company's planned exploration activities, including its drill target strategy and next steps for the Swedish properties; and the Company's interpretations and expectations about the results on the Swedish properties. These statements and other forward-looking information are based on opinions, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate and reasonable in the circumstances, as of the date of this news release, including, without limitation the reliability of exploration and drill results; reliability of data and the accuracy of publicly reported information regarding current, past and historic mines in the Bergslagen district and in respect of the Swedish properties; that the Swedish government will eventually lift or amend its moratorium on uranium exploration and mining in Sweden; the Company's ability to satisfy the terms of the Company's agreement with Boliden; the Company's ability to raise sufficient capital to fund planned exploration activities, maintain corporate capacity; stability in financial and capital markets; the Company's ability to complete its planned exploration programs; the absence of adverse conditions at mineral properties; no unforeseen operational delays; no material delays in obtaining necessary permits; the price of metals remaining at levels that render mineral properties economic; and the ability to realize on the Mineral Resource Estimates Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: the reliability of historic data on District's properties; the Company's ability to raise sufficient capital to finance planned exploration; that the Swedish government maintains its moratorium on uranium exploration and mining in Sweden for the foreseeable future; the Company's limited operating history; the Company's negative operating cash flow and dependence on third-party financing; the uncertainty of additional funding; the uncertainties associated with early stage exploration activities including general economic, market and business conditions, the regulatory process, failure to obtain necessary permits and approvals, technical issues, potential delays, unexpected events and management's capacity to execute and implement its future plans; the Company's ability to identify Mineral Resources and Mineral Reserves; the substantial expenditures required to establish Mineral Reserves through drilling and the estimation of Mineral Reserves or Mineral Resources; the uncertainty of estimates used to calculated mineralization figures; changes in governmental regulations; compliance with applicable laws and regulations; competition for future resource acquisitions and skilled industry personnel; reliance on key personnel; title matters; conflicts of interest; environmental laws and regulations and associated risks, including climate change legislation; land reclamation requirements; changes in government policies; volatility of the Company's share price; the unlikelihood that shareholders will receive dividends from the Company; potential future acquisitions and joint ventures; infrastructure risks; fluctuations in demand for, and prices of metals; fluctuations in foreign currency exchange rates; legal proceedings and the enforceability of judgments; going concern risk; risks related to the Company's information technology systems and cyber-security risks; and risk related to the outbreak of epidemics or pandemics or other health crises. For additional information regarding these risks, please see the Company's Annual Information Form dated July 11, 2022 for the fiscal year ended June 30, 2021, under the heading "Risk Factors", which is available at These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company. These factors and assumptions, however, should be considered carefully. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking information or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Also, many of such factors are beyond the control of the Company. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this news release, and the Company assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. To view the source version of this press release, please visit Sign in to access your portfolio
The Hill
3 hours ago
- The Hill
It's hurricane season again, and public health hangs in the balance
June marks the beginning of the 2025 Atlantic hurricane season, and forecasters are warning of above-average activity. More than half of U.S. coastal areas should plan to face a major hurricane of Category 3, 4, or 5. If our 2024 experience is a reliable predictor, we can anticipate more than $100 billion in damage, more than 100 fatalities and an increasingly problematic, if overlooked, element of these disasters: the threat to public health. Hurricanes and other water-centric events, like flooding, are creating ideal environments for the transmission of infectious diseases, from mold exposure to flesh-eating diseases to mosquito-borne viruses. Clusters of a potentially fatal infection caused by Vibrio bacteria, which can cause severe diarrhea and necrotizing skin lesions, hit Florida after Hurricane Ian in 2023. Cases in 2024 exceeded that total, with high burdens in Florida counties that experienced the worst flooding from Hurricane Helene. In Texas last summer, health officials warned the public of the risk of contracting West Nile virus post-Hurricane Beryl. Mosquito-borne illness is possible wherever there are mosquitoes. Florida, California and Texas all experienced locally acquired cases of dengue fever in 2024. Chikungunya, which can result in lifelong physical debilitation, is also present in the United States, with travel-associated and locally acquired cases being documented in Gulf states as recently as 2019. Several deaths from Eastern equine encephalitis occurred last year in northeastern states, with several towns instituting curfews to curb the mosquito-borne threat. Rises in mosquito populations are a well-documented hazard after hydrologic disasters like hurricanes, tsunamis and floods. These events can compromise sewage pipes, contaminate drinking water and result in diffuse areas of standing water that become breeding grounds for mosquitoes. Emergency preparedness professionals have long understood the risk. What's changing is the frequency of billion-dollar disasters — and with them, we suspect, greater damage, flooding, and disease risk. The good news is that we can leverage past experience, predictive models and tools like state and regional medical stockpiles to mitigate some of the worst health impacts. By strategically positioning medical supplies and countermeasures closer to the point of need, health authorities can significantly reduce response time, minimize logistical challenges and save lives. A number of states already have medical stockpiles for basic medications and personal protective equipment; others are creating or updating legislative authorities for them. These stockpiles generally lack federal support and medical countermeasures for high-consequence threats. The utility of state or regional caches could be expanded to include emerging needs like vaccines, treatments and diagnostics for vector-borne infections. Congress authorized the Department of Health and Human Services to conduct a pilot program matched by local funds for state stockpiling of medical countermeasures and other supplies for public health emergencies. The Biden administration did not request funding for state stockpiles and Congress has not appropriated funds for the program, however, stagnating the initiative. Funding is the number one type of support that jurisdictions say they need to help them establish and maintain stockpiles. Investing in state or regional stockpiles is a cost-effective approach to emergency preparedness. It minimizes the need for last-minute, high-cost procurements during crises, places more autonomy in the hands of states and helps maintain health care system resilience. President Trump's executive order on preparedness recognizes ownership of preparedness at the state and local level, and calls on federal policy to help empower state and local jurisdictions to make smart infrastructure choices. This same ethos can extend to public health preparedness. Last year's final report of the congressional Select Subcommittee on the Coronavirus Pandemic concluded that state stockpiles can provide a tailored local complement to the federal Strategic National Stockpile. As natural disasters increase in frequency and intensity, the federal government can support local decision-makers in meeting their communities' unique public health readiness needs. During COVID-19, many local officials did not know what was in the federal stockpile. Drawing stockpiles closer to the communities that will need them, tied to input from local, state or regional medical advisory groups, would increase awareness of stockpile contents and enable tailored input to support assets these communities need. Redundancies built into state or regional caches could allow local healthcare providers access to critical supplies that allow them to meet medical standards of practice even in a crisis. State stockpiles could facilitate greater efficacy of vendor-managed inventories and improve the quality and efficiency of supply rotations. Especially for countermeasures that have cold chain requirements or other complicated logistics, the federal role can be to provide the training and best practices to allow jurisdictions to successfully store and distribute these assets when needed. COVID-19 revealed a national unpreparedness to increase production rationally based on identifiable gaps pre-disaster. For example, better local input on necessary ventilator functionalities would have improved the production of quality devices as demand surged, rather than devices produced by auto manufacturers that were failures. State and regional stockpiles can reverse this underpreparedness and empower local communities. Congress should show its federal support by extending the authorized timeline for the state stockpile program and, critically, funding it commensurately in the coming appropriations cycle. By strategically positioning medical supplies and countermeasures closer to the point of need, a federal-regional-state partnership can significantly reduce response time, minimize logistical challenges and save lives before future hurricane seasons and other regional disasters occur. Craig Vanderwagen is a former assistant secretary for preparedness and response in the Department of Health and Human Services and the founder and general manager of East West Protection, LLC, which provided private and public sector disaster preparedness support.
